Patients who received an intermediate dose of canakinumab had a reduced occurrence of the primary endpoint, a composite of cardiovascular death, nonfatal acute myocardial infarction, or nonfatal stroke, accompanied by a reduction in IL-6 and CRP [14,15]. This evidence concerns the gene CRP and acute myocardial infarction.